BritishJoumalofCancer(1997)76(9),1170-1180
©1997CancerResearchCampaign
5-Ethynyluracil(GW776):effectsontheformationofthe
toxiccatabolitesof5-fluorouracil,fluoroacetateand
fluorohydroxypropionicacidintheisolatedperfusedrat
livermodel
MArellanol,MMalet-Martinol,RMartino'andTSpector2
'BiomedicalNMRGroup,IMRCPLaboratory,UniversitePaulSabatier,118,routedeNarbonne,31062Toulouse,France;2GlaxoWellcome,5MooreDrive,
ResearchTrianglePark,NC27709,USA
SummaryWestudiedtheeffectsof5-ethynyluracil(GW776),apotentinactivatorofdihydropyrimidinedehydrogenase,onthemetabolismof
5-fluorouracil(5-FU),inparticularwithrespecttoformationofthetoxiccompoundsfluoroacetate(FAC)and2-fluoro-3-hydroxypropionicacid
(FHPA),usingfluorine-19nuclearmagneticresonanceandtheisolatedperfusedratlivermodel.Liverswereperfusedwith5-FUaloneata
doseof15mgkg-'bodyweightorwith5-FU+GW776atdosesof15mg5-FUkg-'bodyweightand0.5mgGW776kg-'bodyweightinjected
1hbefore5-FU.All5-FUwasmetabolizedinexperimentswith5-FUalonewhereasunmetabolized5-FUrepresented94%ofthefluorinated
compoundsmeasuredinexperimentswith5-FU+GW776.GW776modulatedboththecatabolicandtheanabolicpathwaysof5-FU,the
moststrikingeffectbeingonthedegradativepathway.Theamountof5-FUcatabolitesdecreasedbyafactorof27inthepresenceofGW776.
Themodulatorledtoadecreaseina-fluoro-3-alanine(FBAL)formationbyafactorofapproximately110,whilefluorideionformation
decreasedbyafactorofapproximately10.Bystronglyloweringthemetabolismof5-FUintoFBAL,GW776circumventedthetransformation
ofFBALintotoxicFACandFHPA.5-FUanabolitesincreasedbyafactorofapproximately7inthepresenceofGW776.Theleveloffree
fluoronucleotidesand5-fluorouridine-5'-diphosphatesugarswasincreaseduptofivefold.Noincorporationof5-FUintoRNAcouldbe
measuredinexperimentswith5-FUalonewhereas,althoughlow(0.1%of5-FUinjecteddose),itwasdetectableinexperimentswith
5-FU+GW776.TheseresultssuggestthatGW776maybeusefulforattenuatingthenotverycommonbutseriouscardiotoxicand/or
neurotoxicside-effectsof5-FUthatareprobablyduetoFBALmetabolites.
Keywords:5-fluorouracil;5-ethynyluracil(GW776);19Fnuclearmagneticresonance;modulationof5-fluorouracilmetabolism;fluoroacetate;
2-fluoro-3-hydroxypropionicacid;isolatedperfusedratliver
5-Fluorouracil(5-FU)isoneofthemostcommonlyusedanti-
canceragentsfortreatmentofsolidtumours.Commonclinical
adversereactionsincludemyelosuppression,diarrhoea,vomiting
andmucositis.Overthelastdecade,thenumberofreportsof
cardiotoxicityandneurotoxicityattributedto5-FUhasrapidly
increased(Anand,1994;YehandCheng,1994;andreferences
citedtherein).Thebiochemicalmechanismunderlyingthesetoxic
side-effectsremainsunclear,althoughithasbeenpostulatedthat
5-FU,andmorepreciselyitsmaincataboliteex-fluoro-p-alanine
(FBAL)(MukherjeeandHeidelberger,1960;Bemadouetal,
1985;Heggieetal,1987;Hulletal,1988),mightbetransformed
intofluoroacetate(FAC)(KoenigandPatel,1970),ahighly
cardiotoxicandneurotoxicpoison(PattisonandPeters,1966).We
demonstratedontheisolatedperfusedrabbitheartmodelthat
commercialsolutionsof5-FUcontaincardiotoxicimpurities,
namelyfluoromalonicacidsemialdehyde(FMASAld)andfluoro-
acetaldehyde(Facet),thatarederivedfromthedegradationof
5-FUinthebasicmediumrequiredforitssolubilizationandare
Received23December1996
Revised30April1997
Accepted,1May1997
Correspondenceto:MMalet-Martino,IMRCPLaboratory,UniversitePaul
Sabatier,118,routedeNarbonne,31062Toulouse,France
metabolizedintoFACand2-fluoro-3-hydroxypropionicacid
(FHPA),anothercardiotoxiccompound(Lemaireetal,1992,
1994).Moreover,wewerethefirsttodemonstrateexperimentally
thebiotransformationofpure5-FUintotwonewcatabolites,FAC
andFHPA,intheisolatedperfusedratliver(IPRL)modelandin
rats(Arellanoetal,1994).Thisdemonstrationwasextendedtothe
bioconversionof5-FUintoFHPAinhumans(Lemaireetal,
1996).5-FUmetabolismthusprogressesfurtherthanFBAL,
givingrisetotwotoxiccompounds.Wethereforeproposedthat
thecardiotoxicityof5-FUcouldstemfromtwosources:(1)degra-
dationproductsof5-FUformedovertimeinbasicmediumand
(2)metabolismof5-FUitself.
5-Ethynyluracil(GW776)isapotentinactivatorofthecatabolic
pathwayof5-FUactingondihydropyrimidinedehydrogenase
(DPD),theenzymethatconverts5-FUintoitsfirstcatabolite,
5,6-dihydro-5-fluorouracil(FUH2),therebypreserving5-FUfrom
itsrapidandextensivecatabolism(Porteretal,1992;Baccanariet
al,1993;Spectoretal,1993).Increasesinthe5-FUhalf-lifeandin
therenaleliminationofunchanged5-FUwererecentlyreportedin
cancerpatients(Khoretal,1996).GW776greatlyimprovedthe
anti-tumourefficacy,theoralbioavailabilityandthetherapeutic
indexof5-FUinanimals(Baccanarietal,1993;Caoetal,1994).
Moreover,Davisetal(1994)demonstratedthatGW776protected
dogsfrom5-FU-inducedneurotoxicitythatcouldbeduetoFAC
(KoenigandPatel,1970;Okedaetal,1984,1990).
1170
Preventionofformationoftoxiccompoundsfrom5-fluorouracilby5-ethynyluracil1171
Table1LDHactivityandbileflowincontrolliverexperimentsandliverexperimentswith5-FUaloneandwith5-FU+GW776
t(min)
30 60 90 120 150 180 210 240
LDH±s.d.11±4 11±5 19±20 26±27 41±2756±40 66±52 69±28
(mUlmin-1g-1)
incontrol
LDH±s.d.11±6 9±4 14±3 9±2 16±5 35±9 59±25 82±29
(mUlmin-'g-1)
in5-FUalone
LDH±s.d.15±3 8±0 14±11 25±10 46±6 58±12 62±13 68±11
(mUlmin-'-g1)
in5-FU+GW776
Bileflow±s.d.1.27±0.491.05±0.410.90±0.340.76±0.280.48±0.250.21±0.150.12±0.140.09±0.13
(mgmin-'g-1)
incontrol
Bileflow±s.d.1.38±0.141.10±0.311.00±0.180.68±0.120.35±0.100.17±0.050.09±0.050.08±0.04
(mgmin-'g-1)
in5-FUalone
Bileflow±s.d.1.09±0.080.88±0.220.78±0.090.56±0.040.30±0.040.13±0.010.11±0.010.08±0.03
(mgmin-'g-1)
in5-FU+GW776
Thepurposeofthepresentstudywasthustotesttheeffectsof
GW776on5-FUmetabolism,inparticularwithrespecttoforma-
tionofthetoxiccompoundsFACandFHPA,usingfluorine-19
nuclearmagneticresonance('9F-NMR)andtheIPRLmodel.
MATERIALSANDMETHODS
IPRLexperiments
LiversfrommaleWistarrats(IffaCredo,Lyon,France)were
isolatedandperfusedwithrecirculationoftheperfusionmedium
accordingtothedesignoriginallydescribedbyBraueretal(1951)
andmodifiedbySabouraudetal(1993).Therecirculating
perfusate(approximately180ml),oxygenatedwithoxygen-
carbondioxide(95%:5%),wasaKrebs-Ringerbicarbonatebuffer
supplementedwithglucose(1.3mM)andbovineserumalbumin
(0.5%).Theperfusate(pH7.4)wasrecirculatedatameanflowrate
of10mlmin-1g-'ofliver.Theexperimentswerecarriedoutwith
solutionsof5-FUpreparedimmediatelybeforeuseatadoseof15
mgkg-'bodyweight.Forexperimentswith5-FUalone,thedrug
wasinjectedintotheperfusateafter1hofliverequilibration,and
theexperiments(n=5)werecontinuedfor3h.Forexperiments
with5-FU+GW776,5-FUwasinjectedafter1hofliverequilibra-
tioninthepresenceofGW776atadoseof0.5mgkg-'bodyweight
(Spectoretal,1993),andtheexperiments(n=4)werecontinued
for3h.A0.5Msodiumbicarbonatesolutionwascontinuously
infusedintothereservoirtomaintainthepHoftheperfusateat7.4.
ThetemperatureandpHoftheperfusate,portalveinpressureand
bileflowwerecontinuouslymonitored.Bilewascollectedin
preweighedvialsat30-minintervalsafterthebeginningoftheliver
perfusion.Liverviabilitywasassessedbymeasuringlactatedehy-
drogenase(LDH)activityintheperfusateevery30min.
ThepH,vascularresistance,oxygenconsumption,LDHactivity
andbileflowwereintherangeoftheliteraturevalues(Suganoet
al,1978;VanDykeetal,1983).TheevolutionofLDHactivityand
bileflowareshowninTable1.Therewasnosignificantdifference
invaluesofLDHactivityincontrolexperimentsandinexperi-
mentswith5-FUaloneandwith5-FU+GW776.Thebileflow
wasslightlyweakerinexperimentswith5-FU+GW776thanin
controlexperimentsandinexperimentswith5-FUalone,butit
wasintherangeofotherexperimentswith5-FUthatarenot
reportedhere.
Attheendoftheexperiments,analiquotoftheperfusatewas
immediatelyfrozenandkeptat-80°Cuntil'9F-NMRanalysis.
Theremainingperfusatewasfreeze-driedandthenresuspendedin
-3mlofwaterimmediatelybefore19F-NMRanalysis.Bile
samplesweregatheredandstoredat-80°Cuntilanalysis.Liver
wasweighed,immersedinliquidnitrogen,powderedandsequen-
tiallyextractedwithcoldandhot1Mperchloricacidbyusingthe
methodofWainandStaatz(1973).Theacid-solubleandacid-
insolublefractionsthusobtainedwerelyophilizedtodrynessand
storedat-80°Cuntilanalysis.Thelyophilizedmaterialswere
thenresuspendedinapproximately2.5mlofwatercontaining
30mMEDTAimmediatelybefore19F-NMRanalysis.
VerificationofthemetabolicoriginofFACandFHPA
TocheckthattheformationofFACandFHPAwasametabolic
processratherthanachemicaltransformationof5-FUorFBAL
takingplaceduringtheperfusion,severalcontrolexperiments
werecarriedout.
Wefirstcheckedthepurityofthesolutionof5-FUinjectedand
demonstratedthatitwasnotchemicallytransformedinthe
perfusatebubbledwithcarbogenfor3hat37°C.Indeed,the19F-
NMRspectrumoftheperfusionmediumafterconcentrationby
freeze-dryingdisplayedthesingle5-FUpeak.Wealsocarriedout
fourcontrolexperimentsinwhichtheperfusatecontaining5-FUat
aconcentrationof45mgkg-'bodyweight(calculatedforamean
ratbodyweightof400g)wascirculatedfor3hintheperfusion
systemwithoutliver.The'9F-NMRspectraoftheseperfusates
afterconcentrationonlyexhibitedastrongpeakcorrespondingto
BritishJournalofCancer(1997)76(9),1170-11800CancerResearchCampaign1997
1172MArellanoetal
5-FU,whichmadeup99.8±0.07%ofallthefluorinated
compoundsdetected,thefluorideion(F-)signalrepresenting
0.05±0.02%andtwoveryweaksignalsat6=-111.3and
-111.6p.p.m.(0.08±0.05%and0.03±0.01%respectively)not
correspondingtoanyofthesignalsobservedintheconcentrated
perfusatesfromtheIPRLexperimentswith5-FU.
TwocontrolexperimentswerecarriedoutwithFBAL.Wefirst
recordedthe'9F-NMRspectrumofasolutionofFBALinthe
perfusionmediumoveraperiodof3handonlydetectedthe
signalsofFBAL(98.9%)andN-carboxy-a-fluoro-,-alanine
(CFBAL;1.1%).Wealsocarriedoutonecontrolexperiment
inwhichtheperfusatecontainingFBALataconcentrationof
16.6mgkg-'bodyweight(doseequivalentto15mg5-FUkg-'
bodyweightandcalculatedforameanratbodyweightof400g)
wascirculatedfor3hintheperfusionsystemwithoutliver.The
'9F-NMRspectrumofthisperfusateafterconcentrationonly
displayedthesignalsofFBAL,whichmadeup18.3%ofallthe
fluorinatedcompoundsdetected,CFBALrepresenting49.6%,
F-1.4%andtheadductsofFBALwitha-glucose2.4%and
,-glucose28.3%.
NMRspectroscopy
19F-NMRspectrawererecordedat282.4MHzwith'H-decoupling
onaBrukerWB-AM300spectrometerinthefollowingcondi-
tions:probetemperature,25°C;sweepwidth,41667Hz;32768
datapointszero-filledto65536;pulsewidth,7js(flipangle
approximately400innon-concentratedperfusateandbile,approx-
imately300inperchloricacidextractsandapproximately200in
concentratedperfusate);pulseinterval,1.4sforquantificationof
concentratedperfusates,acid-solubleandacid-insolubleextracts
or3.4sforquantificationofnon-concentratedperfusatesandbile
samples;numberofscans,10000-50000;linebroadeningcaused
byexponentialmultiplication,6Hz.Thechemicalshifts(6)were
reportedrelativetotheresonancepeakoftrifluoroaceticacid(5%
w/vaqueoussolution)usedasexternalchemicalshiftreference.
Theconcentrationsofthefluorinatedcompoundsweremeasured
bycomparingtheexpandedareasoftheirNMRsignalswiththat
oftheexternalstandardforquantificationplacedinacoaxial
capillary,namelyasolutionofsodiumparafluorobenzoate
(FBEN)indeuteriumoxidedopedatsaturationwith
chromium(III)acetylacetonate(Cr(acac)3)toshortenthelongitu-
dinalrelaxationtime(T,)ofFBEN.Theapparentconcentrationof
theFBENpeakwaspreviouslycalibrated.Cr(acac)3(approxi-
mately2.5mg)wasalsoaddedtonon-concentratedperfusatesand
bilesamples.Theareasweredeterminedafterthedifferentsignals
werecutoutandweighed.
Fullyrelaxedspectrawereobtainedforallmediaanalysed,even
whenspectrawererecordedwithapulseintervalasshortas1.4s
andwithoutCr(acac)3.Thiswasdemonstratedfor(1)5-FU,FAC
andFHPAinconcentratedperfusatesrecordedwithapulse
intervalof1.4sor3.4swithoutCr(acac)3or10.4swithCr(acac)3,
(2)5-FUandFBALinacid-solubleextractscontainingEDTA
recordedwithapulseintervalof1.4swithoutCr(acac)3or3.4s
withCr(acac)3.Thedifferencesbetweenthevaluesofconcentra-
tionsthusdeterminedwerenotmorethan10%,whichcorresponds
totheprecisionofthemethod(5-10%dependingontheconcen-
tration;Malet-MartinoandMartino,1992).Thehighionic
strengthofconcentratedperfusatesandperchloricacidextracts
andthehighviscosityoftheformermediuminducedadecreaseof
theflipangleforagivenvalueofthepulsewidth(seeabove)and
probablyoftheT1,leadingtoanaccuratequantificationevenwith
alowpulseintervalandwithoutCr(acac)3.
AsastepoflyophilizationwasnecessarytomeasureFHPA
andFACconcentrations,wecheckedtherecoveryofthesetwo
compoundsfromthelyophilizationpellet.Knownamountsof
FHPAandFACwereaddedto450mlofblankperfusateatconcen-
trationsclosetothosefoundintheperfusatesfromratliverexperi-
ments.Three150-mlfractionswerefreeze-driedandtakenupin
waterunderournormaloperatingconditions.'9F-NMRspec-
troscopyshowedthatonly76±2%and63±15%ofFHPAand
FAC,respectively,wererecovered.TheamountsofFHPAandFAC
measuredinourexperimentswerethusunderestimatedasmaterial
remainedinthepellet,whichwasnotcompletelyredissolved.
WenoticedthattheamountsofFBAL(andderivatives)and
F-measuredinconcentratedperfusateswerelowerthaninnon-
concentratedperfusates.OfFBAL(anditsderivatives),71±9%
wasrecoveredinconcentratedperfusatesofexperimentswith
5-FUalone,whereasonly46±10%ofF-wasrecoveredinexper-
imentswith5-FUaloneandwith5-FU+GW776.Thisledusto
quantifyallthe5-FUmetabolitesinnon-concentratedperfusates,
exceptwhentheywerenotdetected(FBALandrelated
compoundsin5-FU+GW776experimentsandFACandFHPAin
5-FUexperiments).
Statisticalanalysis
Allresultswereexpressedasmeans±s.d.Whennecessary,statis-
ticalsignificancewasdeterminedusingStudent'st-test.AP-value
of<0.05wasconsideredtobestatisticallysignificant.
RESULTS
Qualitativeanalysis
IPRLweretreatedwithpure5-FUata'therapeutic'doseof15mg
kg-'bodyweightfor3hwith(n=4)orwithout(n=5)a1-hprior
treatmentwithGW776atadoseof0.5mgkg-'bodyweight
(Spectoretal,1993).
Acharacteristic'9F-NMRspectrumofanon-concentrated
perfusatefromanIPRLtreatedwith5-FUaloneshowsthelarge
signalsof5-FUmaincatabolites,FBALat6=-112.4p.p.m.and
F-comingfromthedefluorinationofFBAL(Martinoetal,1985;
Porteretal,1995)at6=-43.5p.p.m.Lowsignalsfroma-fluoro-
,B-ureidopropionicacid(FUPA)at6=-110.7p.p.m.andCFBAL
derivedfromtheinteractionofbicarbonateionwithFBAL
(Martinoetal,1987)at6=-110.9p.p.m.couldalsobedetected
(FigureIA).Alargesignalof5-FUat6=-93.3p.p.m.anda
weakresonanceforF-wereobservedinthe'9F-NMRspectrum
ofanon-concentratedperfusatefromanIPRLtreatedwith
5-FU+GW776(FigureiB).FUH2wasnotobservedinanyofthe
experiments.
Acharacteristic'9F-NMRspectrumofaconcentratedperfusate
fromanIPRLtreatedwith5-FUalone(Figure2A)showsthe
signalsofFBALat6=-112.6p.p.m.,CFBALat6=-111.4p.p.m.
andF-at6=-49.0p.p.m.Thedifferencesinthevaluesof
chemicalshiftsinnon-concentratedandconcentratedperfusates
aremainlyduetothemuchhigherionicstrengthintheconcen-
tratedperfusatesandtodifferencesinpH(7.6vs8.3respectively).
MoreCFBALwaspresentintheconcentratedperfusates(compare
FiguresIAand2A)astheproportionofCFBALwithrespectto
BritishJournalofCancer(1997)76(9),1170-1180 0CancerResearchCampaign1997
Preventionofformationoftoxiccompoundsfrom5-fluorouracilby5-ethynyluracil1173
A
Reference
FUPA
||CFBALFE
 000-
BAL
 A '* *- -
-40 -60 -80 -100-120-140-160
p.p.m.
B
Reference
FU
 - -
-40 -60 -80-100-120-140-160
p.p.m.
Figure119F-NMRspectraofanon-concentratedperfusatefromanisolatedperfusedratlivertreated(A)with5-FU-alone(15mgkg-1bodyweight)or(B)with
5-FU+GW776(15mg5-FUkg-'bodyweightand0.5mgGW776kg-'bodyweightinjected1hbefore5-FU).(A)pH7.4.(B)pH7.5
FBALincreaseswithpHuptoaboutpH9(Martinoetal,1987).
Thestrongresonanceat6=-111.0p.p.m.andtheweaksignalat
6=-110.4p.p.m.areartifactsoffreeze-drying.Thesetwosignals
onlyappearintheconcentratedperfusatesandcorrespondto
adductsofmetabolicFBALintheRconfiguration(Duschinsky
etal,1973;Ganietal,1985)with5-glucose(FBAL[R]-
gluc,B,6=-111.0p.p.m.)anda-glucose(FBAL[R]-gluca,
6=-110.4p.p.m.).Thetwosignalsat6=-113.6p.p.m.and
-141.3p.p.m.wereassignedtoFHPAandFAC,respectively,and
werepositivelyidentifiedbyspikingaperfusatewithauthentic
standards.ThecontrolexperimentsdescribedinMaterialsand
methodsshowedunambiguouslythatFACandFHPAdidnotarise
fromachemicaltransformationof5-FUorFBALtakingplace
duringtheperfusionexperimentorthefreeze-dryingstepbutwere
formedviaametabolicprocess.Ina'9F-NMRspectrumofa
concentratedperfusatefromanIPRLtreatedwith5-FU+GW776
(Figure2B),alargesignalof5-FUat6=-93.2p.p.m.andlow
signalsfromFBAL[R]-gluc,,CFBAL,FBAL,F-and5-fluorouri-
dine(FUR)at6=-88.0p.p.m.wereobserved.
Inbilesamplesfromexperimentswith5-FUalone(Figure
3A),theresonancesofFBAL(6=-112.4p.p.m.)andF-(6=
-43.5p.p.m.)wereobservedtogetherwiththoseofFBAL
BritishJournalofCancer(1997)76(9),1170-11800CancerResearchCampaign1997
FBAL[R]-glucpj
ReferenceI
CFBAL
FBAL
FHPA
EAC
-40 -60 -80 -100-120-140-160
pp-m.
EU
FBAL[R]-gluco3
CEBAL
FUTJ / FBAL
-40 -60 -80 -100-120-140-160
p-pm.
Fligure219F-NMRspectraofaconcentratedperfusatefromanisolatedperfusedratlivertreated(A)with5-EUalone(15mgkg-1bodyweight)or(B)with
5-EU+GW776(15mg5-EUkg-1bodyweightand0.5mgGW776kg-1bodyweightinjected1hbefore5-EU).(A)pH8.3.(B)pH8.4
conjugateswithbileacids,most probablytheconjugates
withcholic,deoxycholicandmuricholicacids(6= 110.3,
 110.7p.p.m.and 110.9p.p.m.,thelastsignalbeinglowand
observedinonlytwooutoffiveexperiments)(Malet-Martinoet
al,1988;Sweenyetal,1988).A characteristic19F-NMRspectrum
ofa bilesamplefroman experimentwith5-FU+ GW776only
exhibitedthesignalofF-(Figure3B).
Intheacid-solubleextractoflivertreatedwith5-FUalone,the
majorsignalcorrespondedtoFBAL (6= 112.3p.p.m.).The
otherresonances were thoseoffluoronucleotides(FNUCts;
 = 89.2p.p.m.),5-fluorouridine-5'-diphosphatesugars(FUDP
sugars;= 89.1p.p.m.)andunknowncompounds(6= 93.8,
 110.1,110.4and 110.8p.p.m.),whichprobablyarosefrom
chemicaldegradationofFBAL occurringduringthestepinvery
acidicmediumnecessarytoextracttheliver(Figure4A).The
mainsignalfoundintheacid-solubleextractoflivertreatedwith
5-FU+ GW776was thatof5-FU(6= 93.4p.p.m.).FNUCts
andFUDP sugarsledtofourwell-resolvedresonances at =
 89.04,89.07,89.16and 89.27p.p.m.Othersignalswere
thoseofFUR (6= 90.0p.p.m.),FBAL andtheunknown
compoundresonatingat = 93.8p.p.m.(Figure4B).
ThesignalofFBAL (6= 112.3p.p.m.)was theonlyone
detectedintheacid-insolubleextractoflivertreatedwith5-FU
alone(Figure5A).Itprobablycame fromtheincompleteextrac-
tionoftheacid-solublefraction.Ontheotherhand,the'9F-NMR
spectrumofan acid-insolubleextractofa livertreatedwith
BritishJournalofCancer(1997)76(9),1170-1180©CacrRsrhCmpin19
1174MArellanoetal
A
B
Reference
----------JL----A- -1-
0CancerResearchCampaign1997
Preventionofformationoftoxiccompoundsfrom5-fluorouracilby5-ethynyluracil1175
A Reference
.R0 A e 1
FBALconjugateswithbileacidsFBAL
l
 . , I.... II--s-II1-II-
-40 -60 -80 -100-120-140-160
p.p.m.
B Reference
 FLIII .,,
-40 -60 -80 -100-120-140-160
p.p.m.
Figure319F-NMRspectraofabilesamplefromanisolatedperfusedratlivertreated(A)with5-FUalone(15mgkg-1bodyweight)or(B)with5-FU+GW776
(15mg5-FUkg-'bodyweightand0.5mgGW776kg-'bodyweightinjected1hbefore5-FU).(AandB)pH8.5.
5-FU+GW776showedthesignalsof5-fluorouridine-2'-monophos-
phate(2'-FUMP;5=-89.5p.p.m.)and5-fluorouridine-3'-mono-
phosphate(3'-FUMP;8=-89.8p.p.m.),whicharosefromtheacidic
hydrolysisat70°Cof5-FUincorporatedintoRNA(Parisotetal,
1991).Alowsignalof5-fluorouridine-5'-monophosphate(5'-FUMP;
S=-89.2p.p.m.)andtheresonanceof5-FU(S=-93.4p.p.m.)were
alsoobserved(FigureSB).Thesecompoundsprobablycamefrom
theincompleteextractionoftheacid-solublefraction.
Quantitativeanalysis
Globalrecoveryof5-FUanditsmetabolites
ThedataarepresentedinTable2.Theglobalrecoveryisidentical
(approximately67%)inthetwosetsofexperiments.Wecheckedthe
errorofthe'9F-NMRassaybyaddingaknownamountof5-FUto
150mlofblankperfusate(finalconcentration9.5x104M)andby
dosingthreeseparatealiquots.'9F-NMRspectroscopyshowedthat
95.0±0.7%of5-FUwasrecovered.The19F-NMRassayistherefore
accurateandtheerrormadeonitcannotexplainthemissingamount
ofdrugand/ormetabolitesinliverexperiments.Wenoticedthatthere
wasanevaporationofperfusateduringthe4hofperfusion.Toquan-
tifythisloss,wecarriedout12controlexperimentsasfollows.The
perfusatecontaining5-FUataconcentrationof15or45mgkg-'
bodyweight(calculatedforameanratbodyweightof400g),or
FBALor5'-deoxy-5-fluorouridineataconcentrationequivalentto
15or45mg5-FUkg-'bodyweight,respectively,wascirculatedfor
3hintheperfusionsystemwithoutliver.Themeanvolumeof
perfusatelostduringtheseexperimentswas38.9±5.6ml.Thisloss
BritishJournalofCancer(1997)76(9),1170-1180
_ _ _ft%*f -him--th---
F-
I
0CancerResearchCampaign1997
1176MArellanoetal
A
A
S.'
.
..?sE*.b.,......^**.r.u,fjj;i,ii>04:'t,K,AFY!
...:: ....
:'j]k;,;_a;-i ;
w. v..s-xmrws..-..
,Sj,;.,;,l;_.ki;i;,.,_,,_Figure419F-NMRspectraofanacid-solubleextractfromanisolatedperfusedratlivertreated(A)with5-FUalone(15mgkg-lbodyweight)or(B)with
5-FU+GW776(15mg5-FUkg-1bodyweightand0.5mgGW776kg-'bodyweightinjected1hbefore5-FU).(AandB)pH5.4
wasduetothetemperatureintheperfusiondevice,thehighspeed
ofperfusaterecirculationandthehighflowrateofcarbogen
bubbling,bothnecessarytoinsureacorrectoxygenationofthe
liver.Themeanrecoveryoffluorinatedcompoundwas85.6±3.1%,
clearlydemonstratingthatapproximately15%oftheinjecteddose
of5-FU,FBALor5'-deoxy-5-fluorouridinewasevaporatedwith
theperfusateduringtheliverperfusion.Theremainingmissing
drugand/ormetabolites(approximately19%)probablystayedin
theliverthatwasnotcompletelyextractedwiththeextraction
methodologyusedinourstudy.
All5-FUwasmetabolizedinexperimentswith5-FUalone,
whereas64%oftheinjected5-FU(i.e.approximately94%ofthe
fluorinatedcompoundsmeasured)wasrecoveredunchangedin
experimentswith5-FU+GW776.Theamountof5-FUcatabolites
decreasedbyafactorof27inthepresenceofGW776,whereas
5-FUanabolitesincreasedbyafactorof7.
Proportionsof5-FUanditsmetabolites
ThedataarepresentedinTable3.Intheexperimentswith5-FU
alone,FBALwasthemaincataboliteasitrepresented44%ofthe
5-FU-injecteddosewhereasF-,presentintraceamounts,wasthe
maincatabolite(2%ofinjecteddose)intheexperimentswith
5-FU+GW776.
Themaincharacteristicsoftheexperimentswith5-FU+
GW776are(1)thedecreaseinFBALformationbyafactorof
-110,(2)theabsenceofFACandFHPAformation[althoughonly
BritishJournalofCancer(1997)76(9),1170-1180 0CancerResearchCampaign1997

Preventionofformationoftoxiccompoundsfrom5-fluorouracilby5-ethynyluraciI1177
A Reference
FBAL
I. I , ,
-40 -60 -80 -100
p-pm.
-120-140-160
B Reference
I .I
-40
3FUMP
2'FUMP
5'FUMP
EU
-60 -80 -100-120-140-160
pp..M
Fligure5'9F-NMRspectraofanacid-insolubleextractfromanisolatedperfusedratlivertreated(A)with5-FUalone(15mgkg-1bodyweight)or(B)with
5-EU+GW776(15mg5-EUkg-1bodyweightand0.5mgGW776kg-'bodyweightinjected1hbefore5-EU).(AandB)pH5.4
smallamountsofFHPAandFAGwerefoundintheperfusatesof
experimentswith5-FUalone(FHPArepresented0.4%andFAC
0.1I%oftheinjected5-EU)]and(3)theincreasebyafactorof
approximately5ofFNUCtsandFUDPsugarsandthelowbut
measurableincorporationof5-EUintoRNA.
Repartitionof5-FUandmetaboitesinthedifferentmedia
analysed(perfusate,bileandliver)
ThedatapresentedinTable4indicatethat,forallexperiments,
mostofthefluorinatedcompoundswerefoundintheperfusate.
Almostidenticalamountsoffluorinatedcompoundswere
measuredinbilesamplesandacid-insolubleextracts.Ontheother
hand,theproportionoffluorinatedcompoundsismuchhigherin
acid-solubleextractsfromexperimentswith5-EUalone(13%)
thanfromexperimentswith5-EU+GW776(=3%).
FBALandFwerethemaincompoundsinperfusatesfrom
experimentswith5-EUalone(makingup,respectively,approxi-
mately58%andapproximately40%ofthefluorinatedcompounds
measuredinperfusates),whereasunmetabolized5-EUrepresented
approximately97%inperfusatesfromexperimentswith5-EU+
GW776.Only5-EUcataboliteswerefoundinbilesamples,essen-
tiallyFBALandFBALconjugatesin5-EU-aloneexperimentsand
onlyFin5-EU+GW776experiments.Althoughthecatabolic
pathwaywasreducedbyafactorof27when5-EUwasinjectedin
associationwithGW776,thetraceamountofFwasaboutfive-
foldhigherinbilesamplesfromexperimentswith5-EU+GW776.
©CancerResearchCampaign1997 ~~~~~~BritishJournalofCancer(1997)76(9),1170-1180
 --- i --"
 ----- Al1~
 r- I I
 -- NO-- -d MAW" -- .- W^--
...- ...............
.CancerResearchCampaign1997
1178MArellanoetal
Table2Globalrecoveryof5-FUandmetabolitesinexperimentswith5-FUaloneandwith5-FU+GW776
Compounds Percentofinjecteddose±s.d.
Experimentswith5-FUalone Experimentswith5-FU+GW776
Unmetabolized5-FU 0 64±3
Catabolites66±5 2.4±0.8
Anabolites 0.16±0.04a 1.1±0.3a
Total 66±5b 68±4b
aSignificantatP<0.0005.bNotsignificant(P>0.1).
Table3Proportionsof5-FUandmetabolitesinexperimentswith5-FUaloneandwith5-FU+GW776
Compounds Percentofinjecteddose±s.d.
Experimentswith5-FUaloneExperimentswith5-FU+GW776
Unmetabolized5-FU 0 64±3
Catabolites
FUPA 0.6±0.7 0
FBAL 44±lla 0.4±0.2b
F- 22±7 2±1
FACc 0.11±0.04 0
FHPAc,d 0.42±0.06 0
Anabolites
5'FNUCtandFUDPsugars0.16±0.04e 0.8±0.4e
FU-RNA(2'and3'FUMP) 0 0.09±0.01
FUR Of 0.3±0.1
aFBALincludesFBALandCFBALinnon-concentratedperfusate,FBALandFBALconjugateswithbile
acidsinbile,FBALandunknowncompounds(=-93.8,-110.1,-110.4and-110.8p.p.m.)inacid-
solubleextractandFBALinacid-insolubleextract.bFBALincludesFBAL,CFBAL,FBAL[R]-gluc,in
concentratedperfusate,andFBALandunknowncompound(3=-93.8p.p.m.)inacid-solubleextract.
cFACandFHPAcouldonlybeassayedinconcentratedperfusate.dThesignalofFHPAinnon-
concentratedperfusateisinthebaseofthelargesignalofFBAL;itisthusalreadyincludedwhenFBAL
signalisassayed.eSignificantatP<0.01.'Onlyobservedinoneexperimentoutoffive,representing
0.02%ofinjecteddose.
Theamountof5-FUmeasuredinacid-solubleextractsfromexper-
imentswith5-FU+GW776waslowcomparedwiththatofFBAL
inacid-solubleextractsfromexperimentswith5-FUalone,
demonstratingthat5-FU,contrarytoFBAL,isnotstoredinto
hepatocytes.Noanabolitesweredetectedinacid-insoluble
extractsfrom5-FU-aloneexperiments,whereastheexperiments
with5-FU+GW776demonstratedalowincorporationof5-FU
intoRNAofhepatocytes.
DISCUSSION
GW776modulatesboththecatabolicandanabolicpathwaysof5-
FU,themoststrikingeffectbeingonthedegradativepathway.The
amountof5-FUcatabolitesdecreasedbyafactorof27inthepres-
enceofGW776(Table2).Ratliverswerethus>96%inhibited
intheirabilitytocatalyse5-FUdegradation.Thisresultisin
completeagreementwiththestudyofBaccanarietal(1993),
whichreportedthesameextentofinhibitionwhenDPDactivity
wasmeasuredinliverextractsprepared1hor6hafterratswere
treatedwithasingledoseofGW776(2mgkg-'p.o.).
GW776ledtoadecreaseinFBALformationbyafactorof-I10,
whereasFformationdecreasedbyafactorofonly-10(Table3).
L-alanine-glyoxylateaminotransferaseII(AlaAT-II)purifiedfrom
ratlivercatalysedtheeliminationofFfromFBAL.Theenzyme
wasnotinactivatedsignificantlyduringdehalogenationofFBAL,
and5-FUwasnotasubstrate(Porteretal,1995).Toexplainour
data,onemightthereforeevokeaslightdefluorinationofthelarge
amountsofunmetabolized5-FUremainingduringtheexperiments
with5-FU+GW776catalysedbyanotherenzyme.
FACisahighlycardiotoxicandneurotoxicpoison(Pattisonand
Peters,1966)knowntoaccumulateintheorganism(Meldrumand
Bignell1957).WecheckedthecardiotoxicityofFHPAonthe
isolatedperfusedrabbitheartmodelattwodoses,0.01and
1.5mgkg-'.FHPAdidnotgeneratecardiotoxicsymptomsatthe
lowestdosebutwashighlycardiotoxiconthismodelatthehighest
dose(unpublisheddata).Moreover,FBAL,theprecursorofFHPA
andFAC(Arellanoetal,1994),accumulatedinratsandwas
retainedupto8daysinvarioustissues,mainlyliver,heartand
brain(Zhangetal,1992,1993).Bygreatlyloweringthemetabo-
lizationof5-FUintoFBAL,GW776circumventstheformationof
toxicFHPAandFAC(Table3).Thepresentresultstherefore
supporttheearlierreportofDavisetal(1994).Theseauthors
demonstratedthatGW776protecteddogsfromtheneurotoxicity
inducedbya26-hcontinuousinfusionof5-FUatthreedoses(1.6,
4or16mgkg-'24h-')andsuggestedwithothers(Koenigand
Patel,1970;Okedaetal,1984,1990)that5-FUcatabolitesare
responsibleforthisdose-limitingtoxicityindogsandcats,which
areparticularlysensitive.
BritishJournalofCancer(1997)76(9),1170-1180 0CancerResearchCampaign1997
Preventionofformationoftoxiccompoundsfrom5-fluorouracilby5-ethynyluracil1179
Table4Repartitionof5-FUandmetabolitesinperfusate,bileandliver(acid-solubleandacid-insolubleextracts)
fromexperimentswith5-FUaloneandwith5-FU+GW776
Mediumandcompound PercentofInjecteddose±s.d.
Experimentswith5-FUalone Experimentswith5-FU+GW776
Perfusate
5-FU 0 62+3
FUR 0 0.2±0.1a
FUPA 0.6±0.7 0
FBAL 30±9b 0.12±0.07ac
F- 21±7 1.6±0.8
FACa 0.11±0.04 0
FHPAa 0.42±0.06 0
Total 52+5d,e 64±4e
Bile
FBAL 0.13±0.04 0
FBALconjugates 0.3±0.2 0
F- 0.07±0.02' 0.4±0.3f
Total 0.5±0.29 0.4±0.39
Acid-solubleextract
5-FU 0 2.3±0.6
FUR Oh 0.03±0.006
FNUCts 0.16±0.04e 0.75±0.4e
FBAL 12.5±5 0.2±0.1
Unknowncompound(s)0.45±0.06i 0.09±0.04i
Total 13+4e 3.41.1e
Acid-insolubleextract
5-FU 0 0.090.10
5',2'and3'FUMP 0 0.100.03
FBAL 0.17±0.08 0
Total 0.17±0.08g 0.19±0.12g
aFUR,FBAL,FACandFHPAcouldonlybeassayedinconcentratedperfusate.bFBALincludesFBALandCFBAL.
CFBALincludesFBAL,CFBALandFBAL[R]-gluco.dThesignalofFHPAinnon-concentratedperfusateisinthebase
ofthelargesignalofFBAL;FHPAisthusassayedatthesametimeasFBAL.Thisexplainswhythetotaldoesnot
includethevaluefoundforFHPA.eSignificantatP<0.01.'SignificantatP<0.025.sNotsignificant(P>0.1).hOnly
observedinoneexperimentoutoffive,representing0.02%ofinjecteddose.iTheunknowncompoundsresonateat
8=-93.8,-110.1,-110.4and-110.8p.p.m.iOnlytheunknowncompoundresonatingat8=-93.8p.p.m.could
bedetected.
AlsointerestingistheeffectofGW776ontheanabolicpathway
of5-FUthatconferstothedrugitscytotoxicity.GW776increases
thetherapeuticindexof5-FUinmouse(Baccanarietal,1993)and
rat(Caoetal,1994)tumourmodels.AsGW776preventsthe
catabolismof5-FUandthusimprovessystemicexposureto5-FU,
onemightexpectanincreaseintheamountsof5-FUanabolitesto
explainthebetterefficacy.Theliverisnotthebestmodeltostudy
5-FUanabolism.Moreover,thecomparisonbetweenourexperi-
mentswith5-FUaloneandwith5-FU+GW776wouldhavebeen
moreconvincingwithalowerdoseof5-FUwheninjectedin
combinationwithGW776.Weusedthepresentdosetobeable
todetectlowamountsofcatabolites.Nevertheless,ourresults
demonstratethat5-FUanabolitesincreasedbyafactorof-7inthe
presenceofGW776(Table2).TheleveloffreeFNUCtsand
FUDPsugarswasincreasedupto-fivefold(Table3).No5-FU
incorporatedintoRNAwasobservedintheexperimentswith
5-FUalonewhereastheincorporationof5-FUintoRNA,detected
as2'-and3'FUMP,waslow(0.1%oftheinjecteddose)but
detectableintheexperimentswith5-FU+GW776(Table3).
Davisetal(1995)reportedthat,comparedwithmicetreatedwith
5-FUalone,GW776enhancedtheincorporationof5-FJinto
RNAinMOPC-315s.c.tumoursofmice.
Inconclusion,ourstudyclearlyshowsthatGW776prevents
formationofFBALanditssubsequentmetabolismintothetoxic
FHPAandFAC.GW776maythereforebeusefulnotonlyfor
improvingtheefficacyof5-FU(Spectoretal,1994)butalsofor
attenuatingcardiotoxicand/orneurotoxicside-effectsofthisanti-
tumouragentthatmaybeduetoFBALmetabolites.Although
theseside-effectsarenotverycommon,theyaresevereandmay
bedoselimiting.ThecombinationofGW776and5-FUhasgreat
clinicalpotential.GW776increasesthehalf-lifeof5-FUfrom
approximately14mintoapproximately5hinhumans(Khoretal,
1996)andtherebyenablesoraldosingtoreplacethe5-daybolus
andtheprotractedcontinuousinfusionschedules(Baccanarietal,
1993).Moreover,thedrypowderoforallyformulated5-FU
presentstheadvantageofbeingdevoidofcardiotoxicbreakdown
productsfoundini.v.solutions(Lemaireetal,1992).Thiscombi-
nationiscurrentlyinintemationalphaseIIclinicaltrialsforbreast,
pancreatic,colorectalandhepatocellularcancer.
ABBREVIATIONS
5-FU,5-fluorouracil;FBAL,a-fluoro-p-alanine;FAC,fluoro-
acetate;FMASAId,fluoromalonicacidsemi-aldehyde;Facet,
fluoroacetaldehyde;FHPA,a-fluoro-p3-hydroxypropionicacid;
IPRL,isolatedperfusedratliver;GW776,5-ethynyluracil;DPD,
dihydropyrimidinedehydrogenase;FUH2,5,6-dihydro-5-fluo-
rouracil;'9F-NMR,fluorine-19nuclearmagneticresonance;LDH,
BritishJournalofCancer(1997)76(9),1170-11800CancerResearchCampaign1997
1180MArellanoetal
lactatedehydrogenase;EDTA,ethylenediaminetetraaceticacid;F-,
fluorideion;CFBAL,N-carboxy-a-fluoro-p-alanine;FBEN,sodium
parafluorobenzoate;Cr(acac)3,chromium(III)acetylacetonate;
FUPA,ox-fluoro-p-ureidopropionicacid;FBAL[R]-glucp,FBAL
[S]-glucp,FBAL[R]-gluca,FBAL[S]-gluca,adductsofFEBAL
withP-glucoseandoc-glucose;FUR,5-fluorouridine;FNUCts,fluo-
ronucleotides;FUDPsugars,5-fluorouridine-5'-diphosphatesugars;
2'-FUMP,5-fluorouridine-2'-monophosphate;3'FUMP,5-fluorouri-
dine-3'-monophosphate;5'FUMP,5-fluorouridine-5'-monophos-
phate;AlaAT-II,L-alanine-glyoxylateaminotransferase
ACKNOWLEDGEMENTS
Thisworkwassupportedbygrant6635fromtheAssociationpour
laRecherchesurleCancer(toRM)andbygrantfromLigue
NationaleFrantaisecontreleCancer(SectiondesHautes-
Pyr6n6es)toMA.
REFERENCES
AnandAJ(1994)Fluorouracilcardiotoxicity.AnnPharmacother28:374-378
ArellanoM,Malet-MartinoMandMartinoR(1994)Firstdemonstrationthatthe
anticancerdrug,5-fluorouracil,ismetabolizedintheisolatedperfusedratliver
intohighlycardiotoxicfluoroacetate.ProcSocMagneticResonance1320.
BaccanariDP,DavisST,KnickVCandSpectorT(1993)5-ethynyluracil(776C85):
apotentmodulatorofthepharmacokineticsandantitumorefficacyof5-
fluorouracil.ProcNatlAcadSciUSA90:11064-11068
BemadouJ,ArmandJP,LopezA,Malet-MartinoMCandMartinoR(1985)
Completeurinaryexcretionprofileof5-fluorouracilduringasix-day
chemotherapeuticschedule,asresolvedby'9Fnuclearmagneticresonance.
ClinChem31:846-848
BrauerRW,PessottiRLandPizzolatoP(1951)Isolatedratliverpreparation.Bile
productionandotherbasicproperties.ProcSocExpBiolMed78:174-181
CaoS,RustumYMandSpectorT(1994)5-ethynyluracil(776C85):modulationof
5-fluorouracilefficacyandtherapeuticindexinratsbearingadvanced
colorectalcarcinoma.CancerRes54:1507-1510
DavisST,JoynerSS,BaccanariDPandSpectorT(I1994)5-ethynyluracil(776C85):
protectionfrom5-fluorouracil-inducedneurotoxicityindogs.Biochem
Pharmacol48:233-236
DavisST,BaccanariDPandSpectorT(1995)5-ethynyluracil(5EU,776C85):
effectsonthymidylatesynthase(TS)inhibitionandincorporationof5-FUinto
RNAinmicebearings.c.MOPC-315tumors.ProcAmAssocCancerRes36:
292
DuschinskyR,WalkerH,WojnarowskiW,NoackKandBachtoldHP(1973)
(+)-a-fluoro-f-alanine(FBAL),themainmetaboliteof5-fluorouracil(FU)and
itsenantiomer.ProcAmAssocCancerRes14:109
GaniD,HitchcockPBandYoungDW(1985)Stereochemistryofcatabolismofthe
DNAbasethymineandoftheanti-cancerdrug5-fluorouracil.JChemSoc
PerkinTrans1,1363-1372
HeggieGD,SommadossiJP,CrossDS,HusterWJandDiasioRB(I1987)Clinical
pharmacokineticsof5-fluorouracilanditsmetabolitesinplasma,urine,and
bile.CancerRes47:2203-2206
HullWE,PortRE,HerrmannR,BritschBandKunzW(I1988)Metabolitesof5-
fluorouracilinplasmaandurine,asmonitoredby'9Fnuclearmagnetic
resonancespectroscopy,forpatientsreceivingchemotherapywithorwithout
methotrexatepretreatment.CancerRes48:1680-1688
KhorSP,LucasS,HsiehAY,SchilskyR,BurrisH,VonHoffDDandSpectorT
(1996)776C85:effectonrenaleliminationot5-fluorouracilanduracilin
cancerpatients.ProcAmAssocCancerRes37:371
KoenigHandPatelA(1970)Biochemicalbasisforfluorouracilneurotoxicity.Arch
Neurol23:155-160
LemaireL,Malet-MartinoMC,DeFomiM,MartinoRandLasserreB(1992)
Cardiotoxicityofcommercial5-fluorouracilvialsstemsfromthealkaline
hydrolysisofthisdrug.BrJCancer66:119-127
LemaireL,Malet-MartinoMC,MartinoR,DeFomiMandLasserreB(1994)The
Trisformulationof5-fluorouracilismorecardiotoxicthanthesodiumsalt
formulations.Onco/Rep1:173-174
LemaireL,ArellanoM,Malet-MartinoMandMartinoR(1996)Anovelmetabolite
of5-fluorouracilinhumans:2-fluoro-3-hydroxypropionicacid.ProcAmAssoc
CancerRes37:1225
Malet-MartinoMCandMartinoR(1992)Magneticresonancespectroscopy:a
powerfultoolfordrugmetabolismstudies.Biochimie74:785-800
Malet-MartinoMC,BemadouJ,MartinoRandArmandJP(1988)'9FNMR
spectrometryevidenceforbileacidconjugatesofx-fluoro-p-alanineasthe
mainbiliarymetabolitesofantineoplasticfluoropyrimidinesinhumans.Drug
MetabDispos16:78-84
MartinoR,LopezA,Malet-MartinoMC,BemadouJandArmandJP(1985)Release
offluorideionfrom5'-deoxy-5-fluorouridine,anantineoplastic
fluoropyrimidine,inhumans.DrugMetabDispos13:116-118
MartinoR,Malet-MartinoMC,VialaneixC,LopezAandBonM(1987)'9FNMR
analysisofthecarbamatereactionofcx-fluoro-p-alanine,themajorcataboliteof
fluoropyrimidines.ApplicationtoFBALcarbamatedeterminationinbody
fluidsofpatientstreatedwith5'-deoxy-5-fluorouridine.DrugMetabDispos15:
897-904
MeldrumGKandBignellJT(1957)Theuseofsodiumfluoroacetate(compound
1080)forthecontroloftherabbitinTasmania.TheAustVetJ33:186-196
MukherjeeKLandHeidelbergerC(1960)Studiesonfluorinatedpyrimidines.IX.
Thedegradationof5-fluorouracil-6-C'4.JBiolChem235:433-437
OkedaR,KarakamaT,KimuraS,ToizumiS,MitsushimaTandYokoyamaY(1984)
Neuropathologicstudyonchronicneurotoxicityof5-fluorouracilandits
maskedcompoundsindogs.ActaNeuropathol63:334-343
OkedaR,ShibutaniM,MatsuoT,KuroiwaT,ShimokawaRandTajimaT(1990)
Experimentalneurotoxicityof5-fluorouracilanditsderivativesisdueto
poisoningbythemonofluorinatedorganicmetabolites,monofluoroaceticacid
anda-fluoro-p-alanine.ActaNeuropathol81:66-73
ParisotD,Malet-MartinoMC,MartinoRandCrasnierP(1991)'9Fnuclear
magneticresonanceanalysisof5-fluorouracilmetabolisminfourdifferently
pigmentedstrainsofNectriahaematococca.ApplEnvironMicrobiol57:
3605-3612
PattisonFLMandPetersRA(1966)Monofluoroaliphaticcompounds.InHandbook
ofExperimentalPharmacology,SmithFA(ed.),pp.387-458.Springer:New
York
PorterDJT,ChestnutWG,MerrillBMandSpectorT(1992)Mechanism-based
inactivationofdihydropyrimidinedehydrogenaseby5-ethynyluracil.JBiol
Chem267:5236-5242
PorterDJT,HarringtonJA,AlmondMR,ChestnutWG,TanouryGandSpectorT
(1995)Enzymaticeliminationoffluoridefromaz-fluoro-,B-alanine.Biochemn
Pharmacol50:1475-1484
SabouraudA,RedureauM,GiresP,MartinetMandScherrmannJM(1993)Effect
ofcolchicine-specificFabfragmentsonthehepaticclearanceofcolchicine.
DrugMetabDispos21:997-1002
SpectorT,HarringtonJAandPorterDJT(1993)5-ethynyluracil(776C85):
inactivationofdihydropyrimidinedehydrogenaseinvivo.BiochemPharmacol
46:2243-2248
SpectorT,PorterDJT,NelsonDJ,BaccanariDP,DavisST,AlmondMR,KhorSP,
AmyxH,CaoSandRustumYM(1994)5-ethynyluracil(776C85),a
modulatorofthetherapeuticactivityof5-fluorouracil.DrugsFuture19:
565-571
SuganoT,SudaK,ShimadaMandOshinoN(1978)Biochemicalandultrastructural
evaluationofisolatedratliversystemsperfusedwithahemoglobin-free
medium.JBiochem83:995-1007
SweenyDJ,BamesSandDiasioRB(1988)Formationofconjugatesof2-fluoro-
beta-alanineandbileacidsduringthemetabolismof5-fluorouraciland5-
fluoro-2-deoxyuridineintheisolatedperfusedratliver.CancerRes48:
2010-2014
VanDykeRW,GollanJLandScharschmidtBF(1983)Oxygenconsumptionbyrat
liver:effectsoftaurocholateandsulfobromophthaleintransport,glucagon,and
cationsubstitution.AmJPhysiol244:G523-G531
WainWHandStaatzWD(1973)Ratesofsynthesisofribosomalproteinandtotal
ribonucleicacidthroughthecellcycleofthefissionyeast
Schizosaccharomycespombe.ExpCellRes81:269-278
YehKHandChengAL(1994)Acuteconfusioninducedbyahigh-doseinfusionof
5-fluorouracilandfolinicacid.JFormosMedAssoc93:721-723
ZhangR,SoongSJ,LiuT,BamesEandDiasioRB(1992)Pharmacokineticsand
tissuedistributionof2-fluoro-p-alanineinrats.Potentialrelevancetotoxicity
patternof5-fluorouracil.DrugMetabDispos20:113-119
ZhangR,LiuT,SoongSJandDiasioRB(1993)Amathematicalmodelofthe
kineticsandtissuedistributionof2-fluoro-p-alanine,themajorcataboliteof
5-fluorouracil.BiochemPharmacol45:2063-2069
BritishJournalofCancer(1997)76(9),1170-1180 CCancerResearchCampaign1997